About: vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.
Sector: Healthcare
Industry: Biotechnology
Latest price: $29.58 (-2.91%)
VTVT NASDAQ vTv Therapeutics Inc
vTv Therapeutics Inc share price
VTVT price activity
Last Price
$29.580
Change (24hr)
-0.89 USD (-2.91%)
Volume
17.01K
Volume (4w avg)
-
Open
$31.00
Day Range
$29.58 - $31.22
Previous Close
$30.46
Last Trade
13 Oct, 5:53 pm GMT+0
Delayed
13 Oct, 5:53 pm GMT+0
VTVT price performance
Delayed
13 Oct, 5:53 pm GMT+0
VTVT Market Signals